CD274 and clear cell renal carcinoma: Atezolizumab, an anti-PD-L1 antibody with a mutant Fc, showed accumulation in two independent clear cell renal carcinoma xenografts derived from the same patient (10) (4.2 ± 0.6%ID/g and 5.2 ± 0.4%ID/g, Table 1), which mimicked uptake values in a human lung cancer model (11) (3.97 ± 1%ID/g, Table 1).